58148-14-4

Usage

Carboxylic acid derivative

It is a compound that contains a carboxyl group (-COOH) which gives it acidic properties.

Cyclobutane ring

The compound has a four-membered carbon ring structure in its core, which is a characteristic feature of cyclobutane derivatives.

Propyl group attachment

A propyl group (C3H7) is attached to the carboxyl group, which influences the compound's chemical reactivity and properties.

Pharmaceutical industry use

1-propylCyclobutanecarboxylic acid is used as an intermediate in the synthesis of various drugs and pharmaceuticals, contributing to the development of new medications.

Potential pharmacological effects

The compound has shown a variety of potential effects, such as anti-inflammatory and analgesic properties, which could be beneficial in treating pain and inflammation.

Treatment of neurological disorders

Researchers have studied 1-propylCyclobutanecarboxylic acid for its potential use in treating neurological disorders due to its unique chemical structure and properties.

Subject of interest for research and development

The compound's unique chemical structure and potential therapeutic properties make it a valuable subject for further research and development in the pharmaceutical field.

Upstream product

• 3721-95-7 Cyclobutanecarboxylic acid 
• 107-08-4 1-iodo-propane 
• 106-94-5 propyl bromide 

Downstream Products

• 69648-38-0 Methyl-11α,16S-dihydroxy-17,17-propano-9-oxo-prost-13E-en-1-oat 
• 69648-38-0 butaprost 
• 230311-42-9 (2R,3R,4R)-2-[2-(4-carbomethoxyphenyl)ethyl]-3-[(1E)-4-(tert-butyldimethylsiloxy)-5,5-trimethylene-1-octenyl]-4-(tert-butyldimethylsiloxy)-cyclopentan-1-one 
• 230311-44-1 4-(2-{(1R,2R,3R)-3-Hydroxy-2-[(E)-(S)-4-hydroxy-4-(1-propyl-cyclobutyl)-but-1-enyl]-5-oxo-cyclopentyl}-ethyl)-benzoic acid methyl ester 
• 212310-16-2 CAY10399 
• 212310-16-2 CAY10408 

Relevant academic research and scientific papers

ACYCLIC HYDRAZIDES AS CANNABINOID RECEPTOR MODULATORS

The acyclic hydrazides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present inventio

HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention relates to novel hydroxyethylamine compounds of formula (I): (I) having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated-amyloid levels or-amyloid deposits, particularly Alzheimer's disease.

Development of a highly selective EP2-receptor agonist. Part 1: Identification of 16-hydroxy-17,17-trimethylene PGE2 derivatives

Design and synthesis of an EP2-receptor selective agonist began with the chemical modification of α and ω-chains of butaprost 1a, which exhibits an affinity for the IP-receptor. Two series of prostaglandin (PG) analogues with a 16-hydroxy-17,17-trimethylene moiety as an ω-chain were identified. Among those tested, 4a,b,e,f,h and 6a,b,e,f,h were found to be highly selective EP2-receptor agonists. Structure activity relationships are discussed. Copyright

Preparation of 15-deoxy-16-hydroxyprostaglandins

Analogues of PGE1 having the structural formula, STR1 in which J is R-hydroxymethylene or S-hydroxymethylene; R1 is hydrogen; R2 is hydrogen or together with R4 is a methylene chain of 2 to 3 carbon atoms such that a cycloalkyl of 5 to 6 carbon atoms inclusive is formed; R3 is hydrogen or methyl, or together with R4 is a methylene or a lower alkylated methylene chain of 2 to 5 carbon atoms such that a cycloalkyl or a lower alkylated cycloalkyl of 4 to 7 carbon atoms inclusive is formed, or together with R4 is bicycloalkyl or bicycloalkenyl moiety having the formula: STR2 SUCH THAT A BICYCLOALKYL OR BICYCLOALKENYL COMPOUND IS FORMED, WHEREIN M AND N ARE INTEGERS HAVING A VALUE FROM 0 TO 3, P IS AN INTEGER HAVING A VALUE FROM 0 TO 4 AND Q IS AN INTEGER HAVING A VALUE OF FROM 1 TO 4 AND WHEREIN THE DOUBLE BOND OF SUCH BICYCLOALKENYL IS IN THE M, N, P, OR Q BRIDGE; R4 is hydrogen or methyl or together with R2 or R3 forms a cycloalkyl or bicycloalkyl or bicycloalkenyl as defined above, or together with R5 is a methylene chain of 3 to 5 carbon atoms such that a cycloalkyl of 4 to 6 carbon atoms inclusive is formed; R5 is selected from the group consisting of hydrogen, straight-chain alkyl having from 1 to 3 carbon atoms or together with R4 forms a cycloalkyl as defined above; and R6 is hydrogen or straight-chain alkyl having from 1 to 3 carbon atoms are disclosed. Pge1 ester analogues of the above formula, limited to the structures wherein two of R2, R3 R4 and R5 form a cycloalkyl, lower alkylated cycloalkyl, bicycloalkyl or bicycloalkenyl are also disclosed. The prostaglandin analogues selectively produce bronchodilation and decrease gastric secretion in vivo. Methods of preparing the analogues and starting materials required in the synthesis of the analogues are also disclosed.

15-Cyclobutyl-prostaglandins

Prostaglandin analogues of the formula: STR1 wherein A represents a grouping of the formula: STR2 X represents trans-vinylene or ethylene and Y represents cis-vinylene or ethylene, R represents hydrogen or alkyl of 1 through 12 carbon atoms, R1, R2 and R3 represent hydrogen, or alkyl of 1 through 12 carbon atoms or an aryl group, with the proviso that at least one of the symbols R1, R2 and R3 represents an alkyl or aryl group, are new compounds possessing useful pharmacological properties; they are especially useful for the treatment of gastric ulceration.

Synergistic composition comprising PGF2α and PGE2

A synergistic composition comprising as active ingredients a PGF2α compound or its cyclodextrin clathrate thereof and a PGE2 compound or its cyclodextrin clathrate thereof, at a weight ratio of from about 1:0.33 to about 1:1.